Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

World Journal of Gastroenterology

Volumn 22, Issue 38, 2016, Pages 8447-8458

  Merli, Michele ^a   Carli, Giuseppe ^b   Arcaini, Luca ^c   Visco, Carlo ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiviral therapy; Direct acting antiviral agents; Hepatitis C virus; Interferon; Marginal zone lymphomas; Non hodgkin lymphomas; Ribavirin; Sofosbuvir

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; DACLATASVIR; DELEOBUVIR; FALDAPREVIR; PEGINTERFERON; RIBAVIRIN; RITUXIMAB; SIMEPREVIR; SOFOSBUVIR; INTERFERON;

B CELL LYMPHOMA; CANCER GRADING; CLINICAL FEATURE; FOLLICULAR LYMPHOMA; HEPATITIS C; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NODAL MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLENIC MARGINAL ZONE LYMPHOMA; TREATMENT RESPONSE; VIRUS LOAD; WALDENSTROEM MACROGLOBULINEMIA; CLINICAL TRIAL (TOPIC); COMPLICATION; GENOTYPE; LYMPHOMA, B-CELL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GENOTYPE; HEPATITIS C; HUMANS; INTERFERONS; LYMPHOMA, B-CELL; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84991109544     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i38.8447     Document Type: Review

References (68)

1. Suarez F, Lortholary O, Hermine O, Lecuit M. Infectionassociated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034-3044 [PMID: 16397126 DOI: 10.1182/blood-2005-09-3679]
2. Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007; 46: 1234-1242 [PMID: 17566058 DOI: 10.1093/rheumatology/ kem132]
3. Pozzato G, Mazzaro C, Dal Maso L, Mauro E, Zorat F, Moratelli G, Bulian P, Serraino D, Gattei V. Hepatitis C virus and non-Hodgkin' s lymphomas: Meta-analysis of epidemiology data and therapy options. World J Hepatol 2016; 8: 107-116 [PMID: 26807206 DOI: 10.4254/wjh.v8.i2.107]
4. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 327-332 [PMID: 15902713 DOI: 10.1002/jmv.20376]
5. Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006; 15: 2078-2085 [PMID: 17119031 DOI: 10.1158/1055-9965.EPI-06-0308]
6. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S, Talamini R, Holly EA, Grulich AE, Cerhan JR, Hartge P, Cozen W, Boffetta P, Brennan P, Maynadié M, Cocco P, Bosch R, Foretova L, Staines A, Becker N, Nieters A. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-458 [PMID: 18387498 DOI: 10.1016/j.cgh.2008.02.011]
7. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107: 4643-4649 [PMID: 16493005 DOI: 10.1182/ blood-2005-11-4659]
8. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2007; 18: 346-350 [PMID: 17071937 DOI: 10.1093/annonc/ mdl388]
9. Ferreri AJ, Viale E, Guidoboni M, Resti AG, De Conciliis C, Politi L, Lettini AA, Sacchetti F, Dolcetti R, Doglioni C, Ponzoni M. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol 2006; 17: 769-772 [PMID: 16524978 DOI: 10.1093/annonc/mdl027]
10. Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol 2007; 136: 301-304 [PMID: 17233821 DOI: 10.1111/j.1365-2141.2006.06437.x]
11. Tomita N, Kodama F, Takabayashi M, Kawano T, Yamaji S, Fujimaki K, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y. Clinical features and outcome in HCV-positive aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1159-1164 [PMID: 12916868 DOI: 10.1080/1042819031000083055]
12. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006; 24: 953-960 [PMID: 16418500 DOI: 10.1200/JCO.2005.01.5016]
13. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, Pizzolo G, Rodeghiero F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006; 17: 1434-1440 [PMID: 16766591 DOI: 10.1093/annonc/mdl131]
14. Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D'Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2014; 99: 489-496 [PMID: 24270404 DOI: 10.3324/haematol.2013.094318]
15. Arcaini L, Rossi D, Lucioni M, Nicola M, Bruscaggin A, Fiaccadori V, Riboni R, Ramponi A, Ferretti VV, Cresta S, Casaluci GM, Bonfichi M, Gotti M, Merli M, Maffi A, Arra M, Varettoni M, Rattotti S, Morello L, Guerrera ML, Sciarra R, Gaidano G, Cazzola M, Paulli M. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica 2015; 100: 246-252 [PMID: 25381127 DOI: 10.3324/haematol.2014.116855]
16. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Kumada H. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007; 120: 1034-1041 [PMID: 18060923 DOI: 10.1016/j.amjmed.2007.06.022]
17. Su TH, Liu CJ, Tseng TC, Chou SW, Liu CH, Yang HC, Wu SJ, Chen PJ, Chen DS, Chen CL, Kao JH. Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. Hepatology 2016; 63: 721-730 [PMID: 26662347 DOI: 10.1002/hep.28387]
18. Isaacson PG, Berger F, Swerdlow SH, Thieblemont C, Pittaluga S, Harris NL. Splenic B-cell marginal zone lymphoma. In: Swerdlow S, Campo E, Harris NL, et al., ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon: IARC Press; 2008: 218-219
19. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, Feuillard J, Lavergne A, Gordon JI, Berche P, Guillevin L, Lortholary O. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350: 239-248 [PMID: 14724303 DOI: 10.1056/NEJMoa031887]
20. Roggero E, Zucca E, Mainetti C, Bertoni F, Valsangiacomo C, Pedrinis E, Borisch B, Piffaretti JC, Cavalli F, Isaacson PG. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000; 31: 263-268 [PMID: 10685647 DOI: 10.1016/S0046-8177(00)80233-6]
21. Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K, Caggiari L, Lettini AA, Dal Cin E, Ieri R, Freschi M, Villa E, Boiocchi M, Dolcetti R. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586-594 [PMID: 15100336 DOI: 10.1093/ jnci/djh102]
22. Ferreri AJ, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG, Mazzi B, Lettini AA, Demeter J, Dell'Oro S, Doglioni C, Villa E, Boiocchi M, Dolcetti R. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005; 23: 5067-5073 [PMID: 15968003 DOI: 10.1200/ JCO.2005.07.083]
23. Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi E, Incardona P, Brusamolino E, Passamonti F, Burcheri S, Schena C, Pascutto C, Cavanna L, Magrini U, Lazzarino M. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107-115 [PMID: 14692030 DOI: 10.1002/cncr.11893]
24. Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, Besson C, Varet B, Troussard X, Cacoub P, Hermine O. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005; 105: 74-76 [PMID: 15353484 DOI: 10.1182/blood-2004-05-1711]
25. Paulli M, Arcaini L, Lucioni M, Boveri E, Capello D, Passamonti F, Merli M, Rattotti S, Rossi D, Riboni R, Berti E, Magrini U, Bruno R, Gaidano G, Lazzarino M. Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol 2010; 21: 1189-1195 [PMID: 19858084 DOI: 10.1093/ annonc/mdp454]
26. Arcaini L, Varettoni M, Boveri E, Orlandi E, Rattotti S, Zibellini S, Merli M, Lucioni M, Rizzi S, Gotti M, Morello L, Pascutto C, Paulli M. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11: 103-105 [PMID: 21454204 DOI: 10.3816/CLML.2011.n.020]
27. Goldaniga M, Ferrario A, Cortelazzo S, Guffanti A, Pavone E, Ambrosetti A, Marcheselli L, Rossi F, Luminari S, Rossi A, Cro L, Federico M, Lambertenghi Deliliers G, Baldini L. A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. Am J Hematol 2008; 83: 349-354 [PMID: 18186522 DOI: 10.1002/ajh.21065]
28. Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 2015; 90: 197-203 [PMID: 25417909 DOI: 10.1002/ajh.23889]
29. Arcaini L, Ferretti VV, Rossi A, Fogazzi S, Greco A, Baldini L, Balzarotti M, Pioltelli P, Bonfichi M, Varettoni M, Gotti M, Farina L, Ferreri AJM, Laszlo D, Morra E. Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The "Rete Ematologica Lombarda/Hematology Network Of Lombardia Region". Blood 2013; 122: 3003
30. Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94 [PMID: 12110736 DOI: 10.1056/ NEJMoa013376]
31. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877 [PMID: 23425945 DOI: 10.1093/annonc/mds643]
32. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw 2013; 11: 257-272; quiz 273 [PMID: 23486452]
33. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/ j.jhep.2011.02.023]
34. Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment. World J Gastroenterol 2014; 20: 11054-11061 [PMID: 25170194 DOI: 10.3748/wjg.v20.i32.11054]
35. Bauduer F. MALT non-Hodgkin's lymphoma associated with hepatitis C virus infection treated by interferon alpha. Am J Hematol 1996; 53: 209 [PMID: 8895702 DOI: 10.1002/(SICI)109 6-8652(199611)53]
36. Caramaschi P, Biasi D, Carletto A, Ambrosetti A, Mocella S, Randon M, Bambara LM. [MALT lymphomas of the salivary glands. Review of the literature apropos of a case in a patient with hepatitis C virus infection]. Recenti Prog Med 1999; 90: 585-591 [PMID: 10608147]
37. Moccia F, Tognoni E, Boccaccio P. The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection. Ann Ital Med Int 1999; 14: 288-293 [PMID: 10638021]
38. Patriarca F, Silvestri F, Fanin R, Zaja F, Sperotto A, Baccarani M. Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alphainterferon treatment. Br J Haematol 2001; 112: 370-372 [PMID: 11167831 DOI: 10.1046/j.1365-2141.2001.02571.x]
39. Casato M, Mecucci C, Agnello V, Fiorilli M, Knight GB, Matteucci C, Gao L, Kay J. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 2002; 99: 2259-2261 [PMID: 11877309 DOI: 10.1182/blood.V99.6.2259]
40. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM. The effect of antiviral therapy on t(14; 18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001; 97: 1555-1559 [PMID: 11238090 DOI: 10.1182/blood.V97.6.1555]
41. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, Podevin P, Bouscary D, Sogni P, Blanche P, Dreyfus F. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004; 18: 1711-1716 [PMID: 15284859 DOI: 10.1038/sj.leu.2403443]
42. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Lazzarino M, Cavanna L. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23: 468-473 [PMID: 15659492 DOI: 10.1200/JCO.2005.06.008]
43. Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 2009; 145: 255-257 [PMID: 19239472 DOI: 10.1111/ j.1365-2141.2008.07565.x]
44. Arcaini L, Pascutto C, Passamonti F, Bruno R, Merli M, Rizzi S, Orlandi E, Astori C, Rattotti S, Paulli M, Lazzarino M. Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. Int J Cancer 2009; 124: 2246-2249 [PMID: 19132749 DOI: 10.1002/ijc.24162]
45. Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, Merli M, Varettoni M, Chiappella A, Ambrosetti A, Tucci A, Rusconi C, Visco C, Spina M, Cabras G, Luminari S, Tucci M, Musto P, Ladetto M, Merli F, Stelitano C, d'Arco A, Rigacci L, Levis A, Rossi D, Spedini P, Mancuso S, Marino D, Bruno R, Baldini L, Pulsoni A. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014; 25: 1404-1410 [PMID: 24799461 DOI: 10.1093/annonc/mdu166]
46. Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCVassociated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat 2016; 23: 536-544 [PMID: 26924533 DOI: 10.1111/ jvh.12518]
47. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012; 209: 1537-1551 [PMID: 22891273 DOI: 10.1084/jem.20120904]
48. Novara F, Arcaini L, Merli M, Passamonti F, Zibellini S, Rizzi S, Rattotti S, Rumi E, Pascutto C, Vetro A, Astori C, Boveri E, Lucioni M, Paulli M, Zuffardi O, Lazzarino M. High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Hum Pathol 2009; 40: 1628-1637 [PMID: 19647853 DOI: 10.1016/j.humpath.2009.01.025]
49. Peveling-Oberhag J, Crisman G, Schmidt A, Döring C, Lucioni M, Arcaini L, Rattotti S, Hartmann S, Piiper A, Hofmann WP, Paulli M, Küppers R, Zeuzem S, Hansmann ML. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia 2012; 26: 1654-1662 [PMID: 22307176 DOI: 10.1038/leu.2012.29]
50. Ng PP, Kuo CC, Wang S, Einav S, Arcaini L, Paulli M, Portlock CS, Marcotrigiano J, Tarr A, Ball J, Levy R, Levy S. B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood 2014; 123: 1512-1515 [PMID: 24449209 DOI: 10.1182/blood-2013-10-532895]
51. Zibellini S, Capello D, Forconi F, Marcatili P, Rossi D, Rattotti S, Franceschetti S, Sozzi E, Cencini E, Marasca R, Baldini L, Tucci A, Bertoni F, Passamonti F, Orlandi E, Varettoni M, Merli M, Rizzi S, Gattei V, Tramontano A, Paulli M, Gaidano G, Arcaini L. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica 2010; 95: 1792-1796 [PMID: 20511668 DOI: 10.3324/haematol.2010.025437]
52. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 2016; 36. Suppl 1: 47-57 [PMID: 26725897 DOI: 10.1111/liv.13027]
53. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]
54. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898 [PMID: 24725239 DOI: 10.1056/NEJMoa1402454]
55. Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, openlabel phase 2a cohort study. Lancet Infect Dis 2015; 15: 1049-1054 [PMID: 26187031 DOI: 10.1016/S1473-3099(15)00157-7]
56. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, Hezode C, Nader F, Henry L, Hunt S. Sofosbuvir/ velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol 2016; 65: 33-39 [PMID: 26956698 DOI: 10.1016/j.jhep.2016.02.042]
57. Foster GR, Mangia A, Sulkowski M. Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med 2016; 374: 1687-1688 [PMID: 27119242 DOI: 10.1056/NEJMc1601160]
58. Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 2015; 62: 234-237 [PMID: 25285757 DOI: 10.1016/j.jhep.2014.09.031]
59. Sultanik P, Klotz C, Brault P, Pol S, Mallet V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 2015; 125: 2446-2447 [PMID: 25858892 DOI: 10.1182/blood-2014-12-618652]
60. Carrier P, Jaccard A, Jacques J, Tabouret T, Debette-Gratien M, Abraham J, Mesturoux L, Marquet P, Alain S, Sautereau D, Essig M, Loustaud-Ratti V. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 2015; 35: 2222-2227 [PMID: 26104059 DOI: 10.1111/liv.12897]
61. Lim LY, La D, Cserti-Gazdewich CM, Shah H. Lymphoma Remission by Interferon-Free HCV Eradication Without Chemotherapy. ACG Case Rep J 2015; 3: 69-70 [PMID: 26504885 DOI: 10.14309/crj.2015.104]
62. Arcaini L, Besson C, Peveling-Oberhag J, Loustaud-Ratti V, Rattotti S, Ferretti V, Zignego AL, Casato M, Merli M, Hermine O, Visco C. Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection. Blood 2015; 126: 3938
63. Pitini V, Arrigo C, Righi M, Scaffidi M, Sturniolo G. Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol 2004; 124: 252-253 [PMID: 14687039 DOI: 10.1046/j.1365-2141.2003.04751.x]
64. Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Clin Gastroenterol 2004; 38: 360-363 [PMID: 15087696 DOI: 10.1097/00004836-200 404000-00011]
65. Svoboda J, Andreadis C, Downs LH, Miller Jr WT, Tsai DE, Schuster SJ. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma 2005; 46: 1365-1368 [PMID: 16109616 DOI: 10.1080/ 104281905001028289]
66. Oda Y, Kou T, Watanabe M, Sakuma Y, Taguchi N, Kato Y, Kudo Y, Yamauchi A, Sugiura Y, Ohashi S, Asada M, Fukunaga T, Kawaguchi K, Ito H, Nakamura T, Yazumi S. Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin. Dig Dis Sci 2010; 55: 1791-1793 [PMID: 19657737 DOI: 10.1007/ s10620-009-0902-5]
67. Pellicelli AM, Marignani M, Zoli V, Romano M, Morrone A, Nosotti L, Barbaro G, Picardi A, Gentilucci UV, Remotti D, D' Ambrosio C, Furlan C, Mecenate F, Mazzoni E, Majolino I, Villani R, Andreoli A, Barbarini G. Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. World J Hepatol 2011; 3: 278-284 [PMID: 22125661 DOI: 10.4254/wjh.v3.i11.278]
68. Mauro E, Pedata M, Ermacora A, Mazzaro C. An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon. Blood Transfus 2012; 10: 101-103 [PMID: 21839019 DOI: 10.2450/2011.0006-11]